Novo Nordisk CEO says innovation in obesity may justify higher price in some segments

COPENHAGEN (Reuters) - Novo Nordisk's CEO expects more people to take obesity drugs as prices fall over time, he told Reuters on Friday, adding that new generations of the medicine will justify higher prices in some segments.

"I expect that over time we'll see a lower price point that will cater for more and more patients getting on treatment," CEO Lars Fruergaard Jorgensen said in an interview.

Novo's shares rose to new record highs on Thursday after the company announced early trial data for an experimental obesity drug, amycretin.

"You will see new generations of innovations that will cater for even more differentiation, perhaps serve certain comorbidities better, and that can justify a higher price in some segments," Jorgensen said.

(Reporting by Maggie Fick and Jacob Gronholt-Pedersen, editing by Louise Rasmussen)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Qualcomm investor day to detail data center plans Wednesday
• Exclusive: Webull launches private market SPVs for late-stage company access
• Court lifts 250th anniversary deadline for Trump administration to reinstall US park exhibits